Reviewer’s report

Title: Atypical antipsychotics induce human osteoblasts apoptosis via Wnt/β-catenin signaling

Version: 0 Date: 08 Sep 2018

Reviewer: Reviewer 2

Reviewer's report:

PEER REVIEWER COMMENTS: To view the full report from the academic peer reviewer, please see the attached file.

REVIEWER COMMENTS FROM REPORT: The manuscript addresses a relevant topic, the study design is sound, the result presentation is clear and the conclusions are fine.

Some points to improve are:

In the abstract, this sentence is not clear to me: "We cultured human osteoblast cell line hFOB1.19 (OB) treatments with olanzapine, risperidone, amisulpride, aripiprazole or resveratrol combined with one of APs in vitro." Without further explanation I would understand it in a way that these substances are the APs. But why then combine them with the APs? And what has resveratrol to do in this list?

English language editing is needed.

It should be better and earlier motivated/explained why resveratrol was chosen.

In the manuscript its nowhere explained what the CCK-8 assay actually is.

The FACS assay for determining apoptosis needs to be explained better.

Results: "We found that β-catenin protein expression increased compared with control group (Fig.3 A)." I think the authors what to say that it decreases.

It would be helpful to have an immunofluorescence imaging based analysis of the different subcellular localization of β-catenin depending on the presence of the APs and resveratrol.
REQUESTED REVISIONS:

I mentioned some points to improve above. However, these are not major and should be doable easily.

ADDITIONAL REQUESTS/SUGGESTIONS:

See above

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

This reviewer has been recruited by a partner organization, Research Square. Reviewers with declared or apparent competing interests are not utilized for these reviews. This reviewer has agreed to publication of their comments online under a Creative Commons Attribution License attributed to Research Square and was paid a small honorarium for completing the review within a specified timeframe. Honoraria for reviews such as this are paid regardless of the reviewer recommendation.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal